Reuters logo
BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
September 7, 2017 / 12:00 PM / 3 months ago

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

Sept 7 (Reuters) - Adaptimmune Therapeutics Plc

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

* Adaptimmune Therapeutics Plc - ‍Adaptimmune will receive up to £48 million ($61 million) from GSK over course of transition period​

* Adaptimmune Therapeutics Plc - ‍anticipate transition of NY-ESO to GSK to be completed over coming months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below